Market Overview

Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100

Share:
Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares popped Thursday morning, following a note from Credit Suisse that said the stock could trade up by more than 500 percent..

The predicted activity will depend on corporate expenses and the company’s upcoming cystic fibrosis data. PTC is in Phase 3 for its Ataluren Confirmatory Trial in Cystic Fibrosis.

“Risk/reward is very good due to low expectations,” the Credit Suisse note read. “Our near-term focus for shares is upcoming CF data in Q1 2017 readout where we think that investor expectations remain low.”

Related Link: Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One

The U.S. Food and Drug Administration has granted ataluren orphan drug designation for treatment of both cystic fibrosis and Duchenne muscular dystrophy.

Shares of PTC were trading around $13.50 at time of publication, up more than 5.5 percent.

Latest Ratings for PTCT

DateFirmActionFromTo
Jan 2021CitigroupUpgradesNeutralBuy
Dec 2020Raymond JamesMaintainsOutperform
Nov 2020RBC CapitalDowngradesSector PerformUnderperform

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

 

Related Articles (PTCT)

View Comments and Join the Discussion!

Posted-In: Credit SuisseAnalyst Color Long Ideas FDA Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
NVDASusquehannaMaintains625.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com